Pharmacological properties of P2X3-receptors present in neurones of the rat dorsal root ganglia.
1. The electrophysiological actions of several agonists which may differentiate between P2X1- and P2X3-receptors were studied under concentration and voltage-clamp conditions in dissociated neurones of 1-4 day old rat dorsal root ganglia. 2. Beta,gamma-Methylene-D-ATP (beta,gamma-me-D-ATP) (1-300 microM), diadenosine 5',5'''-P1,P5-pentaphosphate (AP5A) (100 nM - 300 microM), diadenosine 5',5'''-P1,P4-tetraphosphate (AP4A) (300 nM - 300 microM) and uridine 5'-triphosphate (UTP) (1 microM - 1 mM) all activated concentration-dependent inward currents with a latency to onset of a few ms. 3. The concentration-response curves for beta,gamma-me-D-ATP and AP5A and ATP had similar maximum values, while that for AP4A had a lower maximum. The concentration-response curve to UTP was shallow and did not reach a maximum. Beta,gamma-Methylene-L-ATP was virtually inactive. The rank order of agonist potency was ATP > AP5A approximately AP4A > beta,gamma-me-D-ATP > UTP > > beta,gamma-methylene-L-ATP. 4. The inward currents were inhibited by the P2-receptor antagonists suramin (100 microM) and pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid (PPADS) (10 microM). PPADS also inhibited responses to ATP (800 nM) and alpha,beta-methylene ATP (2 microM) in a concentration-dependent manner. 5. This study shows that beta,gamma-me-D-ATP, AP5A, AP4A and UTP all act via a suramin- and PPADS-sensitive P2X-receptor to evoke rapid, transient inward currents in dissociated neurones of rat dorsal root ganglia. The very low activity of beta,gamma-methylene-L-ATP suggests that the agonists were acting at the P2X3-subtype to produce these effects.
Rae
M G
MG
Department of Physiology and Pharmacology, University of Strathclyde, Royal College, Glasgow.
Rowan
E G
EG
Kennedy
C
C
D000241:Adenosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D005727:Ganglia, Spinal / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D009474:Neurons / Q000187:drug effects* / Q000502:physiology; D058910:Purinergic P2 Receptor Agonists; D058919:Purinergic P2 Receptor Antagonists; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D051381:Rats; D058477:Receptors, Purinergic P2X3; D013498:Suramin / Q000494:pharmacology
C546410:P2rx3 protein, rat; D058910:Purinergic P2 Receptor Agonists; D058919:Purinergic P2 Receptor Antagonists; D058477:Receptors, Purinergic P2X3; C077792:pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid; D011732:Pyridoxal Phosphate; D013498:Suramin; D000241:Adenosine